Khorana et al developed a score for predicting the risk of venous thromboembolism (VTE) in cancer patients. The authors are from the University of Rochester and Duke University.
NOTE: Several parameters are shared with a previous score reported in 04.28.04.
Parameters:
(1) risk of thrombosis based on type of cancer
(2) prechemotherapy platelet count per µL
(3) hemoglobin in g/dL
(4) prechemotherapy white blood cell count per µL
(5) body mass index (BMI) in kg per square meter
|
Parameter |
Finding |
Points |
|
type of cancer |
stomach, pancreas (very high risk) |
2 |
|
|
lung, lymphoma, gynecologic, bladder, testicular (high risk) |
1 |
|
|
other |
0 |
|
platelet count |
< 350,000 per µL |
0 |
|
|
>= 350,000 per µL |
1 |
|
hemoglobin |
>= 10 g/dL AND no therapy with erythropoietin-like drug |
0 |
|
|
< 10 g/dL OR therapy with erythropoietin-like drug |
1 |
|
white blood cell count |
<= 11,000 per µL |
0 |
|
|
> 11,000 per µL |
1 |
|
BMI |
< 35 kg per square meter |
0 |
|
|
>= 35 kg per square meter |
1 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• The higher the score the greater the likelihood of a venous thromboembolism occurring.
|
Score |
Risk Group |
Short-Term Risk of VTE (median 2.5 months) |
|
0 |
low |
< 1% |
|
1 or 2 |
intermediate |
2% |
|
3 to 6 |
high |
7% |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
